17/08/2025
đź’‰ Experimental Drug Wipes Out Tumors in Early Cancer Trial
A small but promising clinical trial has revealed that a new injectable cancer drug can make aggressive tumors vanish. The treatment, an engineered CD40 agonist antibody called 2141-V11, was tested in 12 patients with advanced cancers, including melanoma and breast cancer.
Results were striking: six patients saw their tumors shrink, while two went into complete remission — with all traces of cancer disappearing from their bodies. Unlike earlier CD40 drugs, which caused dangerous side effects, 2141-V11 was well tolerated. Most side effects were mild, such as fever or injection-site reactions.
What makes this approach different is its delivery. Instead of being infused into the bloodstream, the drug is injected directly into a tumor, where it flips a critical immune “ON” switch. This activates cancer-fighting immune cells and organizes them into structures that act like mini training camps, preparing T-cells to hunt down tumors across the body — even those that weren’t injected.
While the results are groundbreaking, experts caution that the study involved only 12 participants. Larger phase 2 trials are already underway, targeting cancers like brain, bladder, and prostate tumors.
If successful, this therapy could mark a major leap in cancer immunotherapy.
Follow Science Sphere for regular scientific updates
RESEARCH PAPER đź“„
Juan C. Osorio et al, "Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer.", Cancer Cell (August 2025)